Actavis makes pharmaceutical deals look generic. Its $25-billion acquisition (U.S.) of Forest Laboratories follows a familiar formula in the sector. Uppity investor? Check. Low-tax jurisdiction? Check. Buyer’s stock rises? Check. And over $8-billion of value created means financiers will keep busy with their own prescriptions for M&A success.